Stereochemical Analysis of Deuterated Alkyl Chains by MS/MS
摘要:
Vicinally deuterated sec-alkyl phenyl ethers, CH3(CH2)(m)CH(OPh)CHD(CH2)nCH(3), display significant differences in mass spectra between three and erythro stereoisomers. MS/MS experiments, in which parent ions of a single mass are selected and their fragmentation patterns subsequently measured, show that alkene expulsion represents virtually the only decomposition pathway. Two types of MS/MS experiment are reported: mass-analyzed ion kinetic energy (MIKE) spectroscopy of metastable ions and collisionally activated decomposition (CAD) of stable ions. The expulsion of a deuterated alkene from a monodeuterated precursor yields ionized phenol, PhOH.+ (m/z 94). The expulsion of an undeuterated alkene yields PhOD.+ (m/z 95). Without exception, the ratios (PhOD.+/ PhOH.+) from precursors in the three series have values greater than their diastereomers in the erythro series. The ratio of ratios, r = PhOD.+/PhOH.+ for the three divided by PhOD.+/PhOH.+ for the erythro, has a value of 1.2 for the 2-phenoxy-3-deuteriobutanes and larger values for all of the higher homologues up through the monodeuterated phenoxyoctanes (m + n = 4). The highest degree of stereoselectivity, r = 5.8, is measured for 3-phenoxy-4-deuteriohexane. Experiments with multiply deuterated analogues show that alkene elimination is highly regioselective, unlike the corresponding decompositions of ionized sec-alcohols or their acetates. The fact that a large fraction of ionized sec-alkyl phenyl ethers undergo stereospecific syn-elimination means that mass spectrometry has a useful capacity to distinguish one isotopically labeled diastereomer from another.
[EN] HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS MODIFICATEURS D'HÉMOGLOBINE ET LEURS UTILISATIONS
申请人:FRONTHERA U S PHARMACEUTICALS LLC
公开号:WO2017218960A1
公开(公告)日:2017-12-21
Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagnose blood-based diseases, disorders or conditions.
[EN] THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'HORMONE THYROÏDIENNE ET UTILISATIONS ASSOCIÉES
申请人:FRONTHERA U S PHARMACEUTICALS LLC
公开号:WO2019240938A1
公开(公告)日:2019-12-19
Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.